ストックスクリーナーアプリを入手
9.30
10.32%
0.87
アフターアワーズ：
9.43
0.13
+1.40%
前日終値:
$8.43
開ける：
$8.47
24時間の取引高:
2.72M
Relative Volume:
1.98
時価総額：
$829.26M
収益：
$380.79M
当期純損益:
$49.27M
株価収益率:
13.29
EPS:
0.7
ネットキャッシュフロー:
$10.68M
1週間 パフォーマンス:
+16.25%
1か月 パフォーマンス:
+18.17%
6か月 パフォーマンス:
+181.82%
1年 パフォーマンス:
+318.92%
1日の値動き範囲:
$8.46
$9.378
1週間の範囲:
$7.63
$9.378
52週間の値動き範囲:
$2.045
$9.378
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
名前
Amylyx Pharmaceuticals Inc
セクター
電話
617-683-0917
住所
43 THORNDIKE STREET, CAMBRIDGE
AMLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
9.30 | 712.45M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Guggenheim | Buy |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-05-30 | 開始されました | TD Cowen | Buy |
| 2025-04-07 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-11-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-03-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-11 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-24 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-01-05 | 開始されました | BofA Securities | Buy |
| 2022-05-25 | 開始されました | Citigroup | Buy |
| 2022-04-01 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース
H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) - MSN
Signal strength of Amylyx Pharmaceuticals Inc. stock in tech scannersEntry Point & Free AI Powered Buy and Sell Recommendations - Newser
Amylyx Pharmaceuticals (AMLX): A High-Conviction Biotech Play with Avexitide's Groundbreaking Potential - AInvest
Analysts Reaffirm 'Buy' Ratings on Amylyx Pharmaceuticals with High Price Targets - AInvest
Amylyx Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Full technical analysis of Amylyx Pharmaceuticals Inc. stockMarket Growth Report & Entry Point Confirmation Alerts - Newser
What data driven models say about Amylyx Pharmaceuticals Inc.’s futureMarket Movers & Advanced Swing Trade Entry Plans - Newser
Can Amylyx Pharmaceuticals Inc. stock outperform in a bear marketGold Moves & Weekly High Potential Alerts - kangso.co.kr
Market reaction to Amylyx Pharmaceuticals Inc.’s recent newsWeekly Trade Recap & Breakout Confirmation Alerts - Newser
How Amylyx Pharmaceuticals Inc. stock performs during market volatilityChart Signals & Safe Entry Momentum Tips - Newser
Can trapped investors hope for a rebound in Amylyx Pharmaceuticals Inc.Market Trend Report & Growth Oriented Trading Recommendations - Newser
Understanding Amylyx Pharmaceuticals Inc.’s price movementPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Identifying reversal signals in Amylyx Pharmaceuticals Inc.July 2025 PostEarnings & Verified Chart Pattern Signals - Newser
Analyzing Amylyx Pharmaceuticals Inc. with multi timeframe chartsAnalyst Upgrade & Weekly High Conviction Ideas - Newser
11 Best Single Digit Stocks to Buy According to Hedge Funds - Insider Monkey
Amylyx Pharmaceuticals’ Promising Earnings Call Highlights - MSN
Can Amylyx Pharmaceuticals Inc. recover in the next quarterQuarterly Performance Summary & Verified Chart Pattern Trade Signals - Newser
Is Amylyx Pharmaceuticals Inc. reversing from oversold territoryPrice Action & Real-Time Volume Trigger Notifications - Newser
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attention2025 Historical Comparison & Reliable Volume Spike Trade Alerts - 선데이타임즈
What technical models suggest about Amylyx Pharmaceuticals Inc.’s comeback - Newser
Drawdown in Amylyx Pharmaceuticals Inc. May Be Nearing EndMarket Risk Summary & Weekly Stock Breakout Alerts - metal.it
Will Amylyx Pharmaceuticals Inc. rebound enough to break evenMarket Sentiment Report & Real-Time Market Sentiment Alerts - Newser
Amylyx Pharmaceuticals Inc. Inches Above Key Support — Safe to Hold2025 Technical Patterns & Real-Time Market Sentiment Alerts - sundaytimes.kr
Has Amylyx Pharmaceuticals Inc. found a price floorWeekly Investment Recap & High Accuracy Trade Signal Alerts - Newser
What recovery options are there for Amylyx Pharmaceuticals Inc.Market Activity Summary & Consistent Income Trade Recommendations - Newser
Amylyx Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should Know2025 Analyst Calls & Fast Moving Market Watchlists - Newser
XTX Topco Ltd Sells 13,834 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Will Amylyx Pharmaceuticals Inc. benefit from geopolitical trendsMarket Trend Summary & Low Risk Entry Point Tips - newsyoung.net
Can Amylyx Pharmaceuticals Inc. ride the EV waveExit Point & Risk Managed Investment Entry Signals - newsyoung.net
Will Amylyx Pharmaceuticals Inc. benefit from rising consumer demandTrend Confirmation Stock Picks - thegnnews.com
Will Breakout in Amylyx Pharmaceuticals Inc. Sustain Through Next WeekAI Driven Stock Trend Forecast Shows Momentum Shift - beatles.ru
Amylyx Pharmaceuticals Advances ALS Treatment with AMX0114 Clinical Trial - MSN
Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline - MSN
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript - Insider Monkey
Amylyx Reports Q2 EPS of 46c, Meets Consensus Estimate - AInvest
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide’s Advancements - TipRanks
Amylyx Pharmaceuticals Q2 2025 Earnings Preview - MSN
Amylyx Pharmaceuticals: Progress in Trials and Financials - TipRanks
Amylyx Pharmaceuticals: Strategic Progress in Neurodegenerative Therapies and the Path to Long-Term Value - AInvest
Amylyx in 2026: A High-Risk, High-Reward Biotech Catalyst Play - AInvest
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - Yahoo Finance
Amylyx Pharmaceuticals' Q2 2025: Key Contradictions in PBH Patient Estimates, Trial Analysis, and Market Opportunities - AInvest
Amylyx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amylyx Pharmaceuticals’ Phase 3 Study on Avexitide: A Potential Game-Changer for Post-Bariatric Hypoglycemia - TipRanks
Promising Future for Amylyx Pharmaceuticals: Buy Rating Backed by Avexitide’s Market Potential - TipRanks
Amylyx (AMLX) Q2 Net Loss Narrows 43% - Nasdaq
Transcript : Amylyx Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Amylyx Pharma Q2 net loss wider than expected as R&D costs increase - TradingView
Amylyx Pharmaceuticals: A Biotech Undervalued by Momentum and Milestones - AInvest
Amylyx Pharmaceuticals Inc (AMLX) 財務データ
収益
当期純利益
現金流量
EPS
Amylyx Pharmaceuticals Inc (AMLX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mazzariello Gina | Chief Legal Officer |
Aug 12 '25 |
Sale |
8.07 |
15,000 |
121,102 |
171,969 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):